

Special Issue

Biomarkers for Inflammatory and Metabolic Disorders

Message from the Guest Editors

We are pleased to invite you to submit to this new Special Issue, entitled “Biomarkers for Inflammatory and Metabolic Disorders”, of the *Journal of Personalized Medicine*, which highlights the most recent findings concerning to result of biomarkers, development and the role of many factors such as nutrition, diet and the development of rare diseases. The search for biomarkers, particularly in relation to rare diseases, is one of the key goals of personalized medicine and this field is progressing rapidly. Especially important, the development and deployment of high-throughput techniques, combining basic and clinical research, provide an opportunity to speed up the appropriate validation of biomarkers and may potentially contribute to the reduction in diagnostic costs in the future. Therefore, we assume that the presented articles will highlight the latest achievements and clinical utility of biomarkers in the assessment of disease and in clinical follow-up.

Guest Editors

Dr. Aldona Wierzbicka

Department of Biochemistry and Experimental Medicine, Children's Memorial Health Institute, Warsaw, Poland

Dr. Joanna B. Biera

Department of Pathomorphology, Children's Memorial Health Institute, Al. Dzieci Polskich 20, 04-730 Warsaw, Poland

Deadline for manuscript submissions

closed (1 June 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/175598

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).